Another beat, navigated by mature drugs and R&D caps
18/08/17 -"Our target price goes up by c.14% and our recommendation changes from ‘Sell’ to and ‘Add’ as we factor in the robust Q2 17 results, successive guidance upgrades, lower-than-expected generic erosion ..."
Pages
51
Language
English
Published on
18/08/17
You may also be interested by these reports :
26/04/24
The Q1 profits surpassed the street’s expectations, as all the three key molecules witnessed decent growth. Segment-wise, Spain and International ...
26/04/24
Hikma’s qualitative Q1 commentary entailed a positive tone for all the segments. Moreover, the management reaffirmed the full-year guidance. Since ...
25/04/24
The Q1 results topped expectations, led by robust performances across all the key segments. While the management maintained its 2024 guidance, an ...
25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...